基因型特异性微小残留病解读改善儿童急性淋巴细胞白血病危险分层
研究基于英国UKALL2003方案治疗的3113例儿童急性淋巴细胞白血病患者队列,中位随访7年,将诱导结束时聚合酶链反应检测的Ig/TCR基因重排微小残留病(MRD)作为连续变量分析,并按免疫表型、细胞遗传学和荧光原位杂交划分遗传亚型。结果显示不同遗传亚型MRD分布不同(P < .001),疾病水平每降低1个对数级复发风险降低20%(HR,0.80;95%CI,0.77至0.83;P < .001);采用遗传亚型特异性MRD值可更精细地进行危险分层,单一MRD阈值不能反映不同遗传亚型的反应动力学。
要点
- 诱导结束时MRD呈对数正态分布,不同遗传亚型间MRD分布不同(P < .001)。
- 疾病水平每降低1个对数级,复发风险降低20%(HR,0.80;95%CI,0.77至0.83;P < .001)。
- 相同MRD值或类别对应的绝对复发率因遗传亚型而异,单一阈值不能反映各亚型反应动力学。
核心结论
- 单一MRD阈值划分危险组不能反映不同遗传亚型的反应动力学,未来危险分层算法应整合遗传学与MRD以准确识别复发风险最低和最高的患者。
研究设计与样本
- 基于人群的队列研究,纳入在英国UKALL2003方案治疗的3113例患者,中位随访7年。
- 采用聚合酶链反应分析Ig/TCR基因重排评估MRD,依据免疫表型、细胞遗传学和荧光原位杂交划分遗传亚型。
- 将诱导结束时的绝对MRD值进行对数转换,分析其在不同亚组间的分布。
主要发现
- 诱导结束时MRD呈对数正态分布。
- 不同遗传亚型患者的MRD分布不同(P < .001)。
- 良好风险细胞遗传学患者疾病清除最快,高风险遗传学和T细胞急性淋巴细胞白血病患者反应较慢。
- 复发风险与MRD动力学相关,疾病水平每降低1个对数级复发风险降低20%(HR,0.80;95%CI,0.77至0.83;P < .001)。
- 在每个遗传风险组内复发风险与MRD水平直接成比例,但特定MRD值或类别对应的绝对复发率因遗传亚型显著不同。
关键数值与推荐
- 不同遗传亚型间MRD分布差异的P < .001。
- 疾病水平每降低1个对数级,复发风险HR为0.80(95%CI,0.77至0.83;P < .001)。
临床怎么用
- 整合遗传亚型特异性MRD值可更精细地进行危险组分层。
- 作者认为未来危险分层算法应整合遗传学与MRD以准确识别复发风险最低和最高的患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Minimal residual disease (MRD) and genetic abnormalities are important risk factors for outcome in acute lymphoblastic leukemia. Current risk algorithms dichotomize MRD data and do not assimilate genetics when assigning MRD risk, which reduces predictive accuracy. The aim of our study was to exploit the full power of MRD by examining it as a continuous variable and to integrate it with genetics. Patients and Methods We used a population-based cohort of 3,113 patients who were treated in UKALL2003, with a median follow-up of 7 years. MRD was evaluated by polymerase chain reaction analysis of Ig/TCR gene rearrangements, and patients were assigned to a genetic subtype on the basis of immunophenotype, cytogenetics, and fluorescence in situ hybridization. To examine response kinetics at the end of induction, we log-transformed the absolute MRD value and examined its distribution across subgroups. Results MRD was log normally distributed at the end of induction. MRD distributions of patients with distinct genetic subtypes were different ( P < .001). Patients with good-risk cytogenetics demonstrated the fastest disease clearance, whereas patients with high-risk genetics and T-cell acute lymphoblastic leukemia responded more slowly. The risk of relapse was correlated with MRD kinetics, and each log reduction in disease level reduced the risk by 20% (hazard ratio, 0.80; 95% CI, 0.77 to 0.83; P < .001). Although the risk of relapse was directly proportional to the MRD level within each genetic risk group, absolute relapse rate that was associated with a specific MRD value or category varied significantly by genetic subtype. Integration of genetic subtype-specific MRD values allowed more refined risk group stratification. Conclusion A single threshold for assigning patients to an MRD risk group does not reflect the response kinetics of the different genetic subtypes. Future risk algorithms should integrate genetics with MRD to accurately identify patients with the lowest and highest risk of relapse.
引用
- O'Connor D, Enshaei A, Bartram J, et al. Genotype-Specific Minimal Residual Disease Interpretation Improves Stratification in Pediatric Acute Lymphoblastic Leukemia. J Clin Oncol. 2017. PMID: 29131699. doi:10.1200/JCO.2017.74.0449
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。